Early kinetic abnormalities of ApoB-containing lipoproteins in insulin-resistant women with abdominal obesity

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 22, Issue 10, 2002, Pages 1726-1732

  Pont, Frédéric ^a   Duvillard, Laurence ^a   Florentin, Emmanuel ^a   Gambert, Philippe ^a   Vergès, Bruno ^a,b,c  

^a INSERM   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c HÔPITAL DU BOCAGE   (France)

Author keywords

Abdominal obesity; Apolipoprotein B; Insulin; Insulin resistance; Lipids

Indexed keywords

APOLIPOPROTEIN B; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE INTOLERANCE; HUMAN; INSULIN RESISTANCE; ISOTOPE LABELING; LIPOPROTEIN METABOLISM; OBESITY; PRIORITY JOURNAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0036792540     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000032134.92180.41     Document Type: Article

References (46)

1. Björntorp P. Metabolic implications of body fat distribution. Diabetes Care. 1991;14:1132-1143.
2. Björntorp P. Regional obesity. In: Björntorp P, Brodoff BN, eds. Obesity. 1992. Philadelphia, Pa: JB Lippincott Co; 1992:579-586.
3. Reaven GM, Chen YDI. Insulin resistance, its consequences and coronary heart disease: must we choose one culprit? Circulation. 1996;93:1780-1783.
4. Taskinen MR. Insulin resistance and lipoprotein metabolism. Curr Opin Lipidol. 1995;6:153-160.
5. Olefsky JM, Farquhar JW, Reaven GM. Reappraisal of the role of insulin in hypertriglyceridemia. Am J Med. 1974;57:551-560.
6. Garg A, Helderman JH, Koffler M, Ayuso R, Rosenstock J, Raskin P. Relationship between lipoprotein levels and in vivo insulin action in normal young white men. Metabolism. 1988;37:982-987.
7. Egusa G, Beltz WF, Grundy SM, Howard BV. Influence of obesity on the metabolism of apolipoprotein B in humans. J Clin Invest. 1985;76:596-603.
8. Kesaniemi YA, Beltz WF, Grundy SM. Comparison of metabolism of apolipoprotein B in normal subjects, obese patients, and patients with coronary heart disease. J Clin Invest. 1985;76:586-595.
9. Kissebah AH, Alfarsi S, Adams PW. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in man: normolipemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia. Metabolism. 1981;30:856-868.
10. Cummings MH, Watts GF, Pal C, Umpleby M. Hennessy TR, Naoumova R, S6nksen PH. Increased hepatic secretion of very low density lipoprotein apolipoprotein B 100 in obesity: a stable isotope study. Clin Sci. 1995;88:225-233.
11. Schaefer JR, Rader DJ, Brewer HB. Investigation of lipoprotein kinetics using endogenous labeling with stable isotopes. Curr Opin Lipidol. 1992;3:227-232.
12. Shames DM, Havel RJ. De novo production of low density lipoproteins: facts or fancy. J Lipid Res. 1991;32:1099-1112.
13. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel 111). Washington, DC: National Institutes of Health: 2001. Publication No. (NIH) 01-3670.
14. Matthews DR, Hosker JP, Rudenski BA, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
15. Shen DC, Shien SM, Fuh MMT, Wu DA, Chen YDI, Reaven GM. Resistance to insulin-stimulated-glucose uptake in patients with hypertension. J Clin Endocrinol Metab. 1988;66:580-583.
16. Taskinen MR, Packard CJ, Sheperd J. Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM. Diabetes. 1990;39:1017-1027.
17. Vergès B, Rader D, Schaefer J, Zech L, Kindt M, Fairwell T, Gambert P, Brewer HB Jr. In vivo metabolism of apolipoprotein A-IV in severe hypertriglyceridemia: a combined radiotracer and stable isotope kinetic study. J Lipid Res. 1994;35:2280-2291.
18. Pont F, Duvillard L, Maugeais C, Athias A, Persegol L, Gambert P, Vergès B. Isotope ratio mass spectrometry, compared with conventional mass spectrometry in kinetic studies at low and high enrichment levels: application to lipoprotein kinetics. Anal Biochem. 1997;248:277-287.
19. Duvillard L, Pont F, Florentin E, Gambert P. Vergès B. Significant improvement of apolipoprotein B-containing lipoprotein metabolism by insulin treatment in patients with non-insulin-dependent diabetes mellitus. Diabetologia. 2000;43:27-35.
20. Cohn JS, McNamara JR, Cohn SD, Ordovas JM, Schaefer EJ. Plasma apolipoprotein changes in the triglyceride-rich lipoprotein fraction of human subjects fed a fat-rich meal. J Lipid Res. 1988;29:925-936.
21. Yarasheski KE, Smith K, Rennie MJ, Bier DM. Measurement of muscle protein fractional synthetic rate by capillary gas chromatography/combustion isotope ratio mass spectrometry. Biol Mass Spectrom. 1992;21:486-490.
22. Hard WH, Demmelmair H, Jauch KW, Schmidt HL, Koletzko B, Schildberg FW. Determination of protein synthesis in human rectal cancer in situ by continuous [1-13C]leucine infusion. Am J Physiol. 1997;272:E796-E802.
23. Cobelli C, Toffolo G, Foster DM. Tracer-to-tracee ratio for analysis of stable isotope tracer data: link with radioactive kinetic formalism. Am J Physiol. 1992;262:E968-E975.
24. Barrett PHR, Bell BM, Cobelli C, Golde H, Schumitzky A, Vicini P, Foster DM. SAAM II: simulation, analysis and modeling software for tracer and pharmacokinetic studies. Metabolism. 1998;47:484-492.
25. Pont F, Duvillard L, Vergès B, Gambert P. Development of compartmental models in stable isotope experiments: application to lipid metabolism. Arterioscler Thromb Vasc Biol. 1998;18:853-860.
26. Millar JS, Lichtenstein AH, Cuchel M, Dolnikowski GG, Hachey DL, Cohn JS. Schaefer EJ. Impact of age on the metabolism of VLDL, IDL, and LDL apolipoprotein B-100 in men. J Lipid Res. 1995;36:1155-1167.
27. Nikkilä EA, Kekki M. Plasma triglyceride transport kinetics in Diabetes Mellitus, Metabolism. 1973;22:1-22.
28. Dagher FJ, Lyons JH, Finlayson DC, Shamsai J, Moore FD. Blood volume measurement: a critical study. Adv Surg. 1965;1:69-109.
29. Landin K, Lonnroth P, Krotkiewski M, Holm G, Smith U. Increased insulin resistance and fat cell lipolysis in obese but not lean women with a high waist/hip ratio. Eur J Clin Invest. 1990;20:530-535.
30. Kissebah AH, Peiris AN. Biology of regional body fat distribution: relationship to non-insulin-dependent diabetes mellitus. Diabetes Metab Rev. 1989;5:83-109.
31. Jackson TK, Salhanick AI, Elovson J, Deichman ML, Amatruda JM. Insulin regulates apolipoprotein B turnover and phosphorylation in rat hepatocytes. J Clin Invest. 1990;86:1746-1751.
32. Salhanick AI, Schwartz SI, Amatruda JM. Insulin inhibits apolipoprotein B secretion in isolated human hepatocytes. Metabolism. 1991;40:275-279.
33. Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G. Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apo B production in normal weight and obese individuals. Diabetes. 1993;42:833-842.
34. Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest. 1995;95:158-166.
35. Cummings MH, Watts GF, Umpleby AM, Hennessy TR, Kelly JM, Jackson NC, Sönksen PH. Acute hyperinsulinemia decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetes. 1995;44:1059-1065.
36. Malmström R, Packard CJ, Caslake M, Bedford D, Stewart P, Yki-Jarvinen H, Sherperd J, Taskinen MR. Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects. Diabetes. 1998;47:779-787.
37. Sparks JD, Sparks CE. Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion. Biochim Biophys Acta. 1994;1215:9-32.
38. Adeli K, Theriault A. Insulin modulation of human apolipoprotein B mRNA translation: studies in an in vitro cell-free system from HepG2 cells. Biochem Cell Biol. 1992;70:1301-1312.
39. Sparks JD, Phung TL, Bolognino M, Sparks CE. Insulin-mediated inhibition of apolipoprotein B secretion requires an intracellular trafficking event and phosphatidylinositol 3-kinase activation: studies with brefeldin A and wortmannin in primary cultures of rat hepatocytes. Biochem J. 1996;313:567-574.
40. Wetterau JR, Lin MC, Jamil H. Microsomal triglyceride transfer protein. Biochim Biophys Acta. 1997;1345:136-150.
41. Taghibiglou C, Carpentier A, Van Iderstine SC, Chen B, Rudy D, Aiton A, Lewis GF, Adeli K. Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance: evidence for enhanced lipoprotein assembly, reduced intracellular apoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model. J Biol Chem. 2000;275:8416-8425.
42. Guerci B, Vergès B, Durlach V, Hadjadj S, Drouib P, Paul JL. Relationship between altered postprandial lipemia and insulin resistance in normolipidemic and normoglucose tolerant obese patients. Int J Obes. 2000;24:468-478.
43. Gianturco SH, Bradley WA, Gotto AM Jr, Morrisett JD, Peavy DL. Hypertriglyceridemic very low density lipoproteins induce triglyceride synthesis and accumulation in mouse peritoneal macrophages. J Clin Invest. 1982;70:168-178.
44. Anber V, Millar JS, McConnell M, Shepherd J, Packard CJ. Interaction of very-low-density, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans. Arterioscler Thromb Vasc Biol. 1997;17:2507-2514.
45. Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol. 1998;81:13B-17B.
46. Hodis HN, Mack WJ. Triglyceride-rich lipoproteins and progression of atherosclerosis. Eur Heart J. 1998;19(suppl A):A40-A44.